Miller, Mark Thomas,Anderson, Corey,Arumugam, Vijayalaksmi,Bear, Brian Richard,Binch, Hayley Marie,Clemens, Jeremy J.,Cleveland, Thomas,Conroy, Erica,Coon, Timothy Richard,Frieman, Bryan A.,Grootenhui
申请号：
AU2020220185
公开号：
AU2020220185A1
申请日:
2020.08.21
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
#$%^&*AU2020220185A120200910.pdf#####ABSTRACT The present invention features a compound of formula (I): W OZ, x z' (R1)n A B (R2)p (Y)0 C (R3)q (1) or a pharmaceutically acceptable salt thereof, where R 1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
